Smartwatch for poor sleep and nightmares in service members with PTSD or brain injury
Tests a wearable smartwatch for insomnia and nightmares in military service members.
Key facts
- Who runs it
- Uniformed Services University of the Health Sciences
- Where
- Bethesda and Minneapolis, United StatesSee the 2 sites
- Trial code
- Registry title
- INSIGHT: Insomnia, Nightmares, and Sympathetic Hyperactivity Intervention
- Status
- Not yet recruiting
- People taking part
- 180 people, planned
- Started
- 1 Jun 2026
- Expected to end
- Dec 2027
- Type of study
- Interventional, 2 groupsOne group gets a sham (pretend) treatment, for comparison.
- Treatments tested
- NightWare smartwatch configured to detect physiological signs of sympathetic activation during sleep, such as heart-rate spikes and movement patterns.
- Sham (No Treatment)
- Record updated
- 28 April 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for current or former military service members. Some are healthy, and some are poor sleepers with or without PTSD or brain injury (TBI). It tests the NightWare smartwatch against a sham watch.
- Age
- 18 to 62 years
- Sex
- All sexes
- Disease stage
- Poor sleepers (insomnia), with or without PTSD and TBI, plus a healthy control group. Usual bedtime must be between 9:00 PM and 1:00 AM.
- Earlier treatment
- No alpha or beta-receptor active medicines or prescribed sleep aids in the last 3 months. No SNRIs or SSRIs started in the last 3 months. No other sleep medicine or supplement started in the last 90 days. No current sleep therapy such as CBT-I.
Main reasons for not taking part
- Pregnancy
- Moderate or severe obstructive sleep apnea (STOP-BANG greater than 5 or AHI≥15)
- Serious or unstable medical, neurological, heart, psychiatric or sleep condition, or clinically significant suicidality
- Excessive alcohol use (AUDIT-C > 3), high nicotine or caffeine dependence, or substance use treatment within 90 days
- Routine night shift work in the past 3 months, or narcolepsy, shift-work or circadian rhythm disorders
The registry criteria, word for word
Show all 29 criteriaShow less
Who can take part
- Defense Enrollment Eligibility Reporting System (DEERS) Eligible
- Current or former military service member
- Able to read and understand English language without the use of an interpreter
- Habitual bedtime between 9:00 PM and 1:00 AM
- Aged 18-62 (inclusive)
- Able to commit to study procedures
Who cannot take part
- Use of alpha or beta-receptor active medications or prescribed sleep aids in the last 3 months
- Receiving ongoing and extensive treatment for a new or acute psychiatric disorder within 90 days, other than routine follow-up and care
- Starting concurrent evidence based psychiatric treatment within the past three months
- Started using any other medication (prescribed or over-the-counter) for the purpose of improving sleep in the last 90 days (e.g., barbiturates, benzodiazepines, melatonin, natural supplements and herbs, antidepressants, antihistamines, etc.)
- Receiving treatment for substance use disorder within 90 days from the start of the study
- Currently in therapy for the primary purpose of improving sleep (e.g., CBT-I)
- Exclusion for optional MRI visit:; Metal in body that is ferromagnetic / incompatible with MRI or other safety issues and indicated by screen Previous adverse reactions to sleep deprivation Illicit drug use as determined by participant self-report Alcohol in system at time of MRI overnight as determined participant self report Nicotine use in the last 3 months; For poor sleep group:; TBI History of epilepsy or suspected seizure disorder
- Diagnosis of a serious medical condition (i.e., late-stage cancer or heart disease)
- Unstable neurological disease/autonomic disorders/ heart conditions/psych/ sleep or other unstable disorder as determined by the Principal Investigator/Associate
- History or diagnosis of any of the following sleep disorders: narcolepsy, shift-work disorder or circadian rhythm disorders
- Prone to problems with venipuncture including fainting, hematoma, and infection
- Currently experiencing a neurological disorder (e.g., stroke, Parkinson's, MS, etc.)
- Started use of SNRIs or SSRIs in the last 3 months
- Pregnant
- Routine night shift work in the past 3 months
- Investigators determined by clinical interview by Mini international neuropsychiatric interview and medical health questionnaire
- Excessive alcohol use as determined by the AUDIT-C (AUDIT-C > 3)
- Evidence of moderate or severe Obstructive Sleep Apnea (OSA): Determined by the STOP-BANG questionnaire: STOP-BANG greater than 5 Determined by EMR PSG records: moderate or severe OSA [apnea-hypopnea index (AHI)≥15]
- Clinically significant suicidality as assessed by the Columbia-Suicide Severity Rating Scale (C-SSRS)
- Currently participating in other research studies for improving sleep
- Currently participating in other research studies for improving PTSD
- Currently undergoing other treatment to improve sleep (e.g., acupuncture)
- Moderate and high nicotine dependence based on the Fagerstrom Test for Nicotine Dependence (> 4 on the Fagerstrom Test for Nicotine Dependence) High caffeine dependence based on the Caffeine Dependence Questionnaire (> 30 on the Caffeine Dependence Questionnaire)
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 62 years old?
Where in United States
- Walter Reed National Military Medical Center/Uniformed Services UniversityBethesda, United StatesContact: Kent CDR Werner, MD/Ph.D.Not yet recruiting
- University of MinnesotaMinneapolis, United StatesContact: Nicholas Dr. Davenport, Ph.D.Not yet recruiting
About the trial
What the trial wants to find out
The INSIGHT study is a multi-site clinical research program designed to examine how insomnia and symptoms of sympathetic hyperactivity impair sleep, cognition, and physiological restoration in warfighters, and to evaluate whether a wearable therapeutic device can improve these outcomes. Warfighters with a history of traumatic brain injury, post-traumatic stress disorder, or chronic operational stress commonly report disrupted sleep accompanied by manifestations of nocturnal sympathetic activation such as diaphoresis, palpitations, hyperarousal, and nightmares. These symptoms erode sleep quality, reduce cognitive performance, and undermine psychological resilience and operational readiness. Insomnia is two to three times more common in military populations than in civilians, and both TBI and PTSD independently elevate the risk for dysregulated autonomic tone. Excessive sympathetic activity during REM sleep disrupts the normally quiescent locus coeruleus state required for adaptive emotional processing and may contribute to the genesis of nightmares. Excessive sympathetic tone may also interfere with deep NREM-dependent glymphatic clearance, a recently discovered mechanism that supports cognitive restoration and metabolic waste removal. Yet, no study has comprehensively linked these physiological processes in warfighters or evaluated whether wearable-derived autonomic measures can meaningfully stratify insomnia phenotypes. The INSIGHT protocol addresses this gap through a two-phase design integrating multimodal biomarker collection, wearable technology validation, advanced imaging, and a randomized controlled intervention. Phase 1 enrolls 250 participants (50 healthy controls and 200 poor sleepers with or without PTSD and TBI) who undergo structured screening, cognitive testing, and detailed baseline assessments before completing a 2-week at-home data collection period. During this period, participants wear a suite of devices, including EEG headbands, ECG patches, PPG-based sensors, accelerometry rings, blood pressure devices, temperature sensors, and smartwatches, to capture autonomic activity, sleep architecture, cardiovascular and respiratory variability, movement, sudomotor activity, and circadian body temperature patterns. Ecological momentary assessments administered three times daily track fluctuations in sleep quality, mood, PTSD symptoms, and daytime functioning, while urine samples collected on the final three days allow for biochemical analysis of hormonal and sympathetic biomarkers. After the at-home period, all participants complete an overnight in-lab polysomnogram combined with fNIRS to measure sleep stages, autonomic dynamics, cerebral hemodynamics, and glymphatic signatures. A subset of participants also completes an optional overnight MRI with simultaneous EEG following controlled sleep deprivation, enabling state-of-the-art imaging of human glymphatic activity using the MAGNUS MRI platform. This optional visit provides unprecedented insight into how TBI, PTSD, and insomnia alter the physiology of sleep-dependent brain fluid dynamics. In Phase 2, all poor sleepers enter a double-blind, sham-controlled, 30-day randomized trial testing the therapeutic potential of the NightWare smartwatch. NightWare detects sympathetic surges during sleep through heart rate elevations and movement patterns and delivers brief haptic vibrations aimed at interrupting escalating autonomic arousal. Although originally cleared for nightmare treatment, its mechanism is well suited for SNH-related insomnia more broadly. Participants use the device daily while continuing EMA surveys, wearable monitoring, and cognitive assessments, generating rich physiological and behavioral data throughout the intervention. The primary goal is to determine whether reducing nocturnal sympathetic spikes leads to measurable improvements in sleep quality, autonomic stability, daytime functioning, and symptom burden. In parallel, Phase 2 data enable development of the Multi-Organ Autonomic Index of Sleep, an integrated biomarker model that combines neurological, cardiovascular, respiratory, and dermal signals to predict treatment response and classify insomnia subtypes.
Read full original descriptionShow less
The INSIGHT study will produce the most comprehensive dataset to date linking autonomic physiology, glymphatic function, sleep architecture, wearable-derived biomarkers, cognition, and clinical outcomes in warfighters. By identifying physiological signatures of sympathetic hyperarousal and determining whether a non-pharmacological wearable intervention can meaningfully improve sleep, INSIGHT directly supports Department of Defense priorities to enhance readiness, resilience, and long-term neurological health in service members. Wearable tools capable of monitoring and improving sleep outside the laboratory have the potential to transform both clinical care and operational performance, offering scalable and accessible approaches to restoring sleep and optimizing recovery.
The 2 groups in the trial
- Control ArmSham treatment, for comparison
Participants assigned to the sham intervention receive an outwardly identical NightWare smartwatch that does not deliver haptic interventions in response to stress physiology. The sham device collects the same passive physiological data but does not actively attempt to modify sleep or autonomic activity. This arm controls for placebo effects, device expectations, and nightly wear. Participants follow the same 30-day procedures, including daily surveys and physiological sensor wear, ensuring all aspects of participation are identical except for the therapeutic haptic function.
Treatment: Sham (No Treatment)
- Intervention ArmTreatment being tested
Participants assigned to the active intervention receive a functioning NightWare smartwatch configured to detect physiological signs of sympathetic activation during sleep, such as heart-rate spikes and movement patterns. When these stress signals exceed a preset threshold, the device delivers brief, gentle haptic vibrations designed to interrupt escalating autonomic arousal without fully awakening the user. The goal is to reduce nighttime sympathetic hyperactivity, improve sleep continuity, and alleviate insomnia symptoms. Participants wear the device nightly for 30 days and complete daily surveys and physiological monitoring to assess treatment effects.
Treatment: NightWare smartwatch configured to detect physiological signs of sympathetic activation during sleep, such as heart-rate spikes and movement patterns.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Insomnia, Nightmares, and Sympathetic Hyperactivity Intervention in the warfiGHTer (INSIGHT)
- Plain-language title
- Smartwatch for poor sleep and nightmares in service members with PTSD or brain injuryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Criteria questions
- Built from NCT07288593, who can take part
- Record updated
- 28 April 2026